Skip to main content

Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model

  • 2022-07-09
  • Microorganisms 10(7)
    • N. Iyer
    • Michelle A Williams
    • A. O’Callaghan
    • E. Dempsey
    • R. Cabrera-Rubio
    • Mathilde Raverdeau
    • F. Crispie
    • P. Cotter
    • S. Corr

Abstract

The use of probiotics such as Lactobacillus and Bifidobacterium spp. as a therapeutic against inflammatory bowel disease (IBD) is of significant interest. Lactobacillus salivarus strain UCC118TM is a commensal that has been shown to possess probiotic properties in vitro and anti-infective properties in vivo. However, the usefulness of UCC118 TM as a therapeutic against colitis remains unclear. This study investigates the probiotic potential of Lactobacillus salivarius, UCC118™ in a mouse model of colitis. DSS-induced colitis was coupled with pre-treatment or post-treatment with UCC118TM by daily oral gavage. In the pre-treatment model of colitis, UCC118TM reduced the severity of the disease in the early stages. Improvement in disease severity was coupled with an upregulation of tissue IL-10 levels and increased expression of macrophage M2 markers. This anti-inflammatory activity of UCC118TM was further confirmed in vitro, using a model of LPS-treated bone marrow-derived macrophages. Taken together, these results suggest that UCC118TM may promote the resolution of inflammation. This was supported in a mouse model of established DSS-induced colitis whereby UCC118TM treatment accelerated recovery, as evidenced by weight, stool, histological markers and the recovery of microbiome-associated dysbiosis with an increased abundance of beneficial commensal species. These results demonstrate the potential of Lactobacillus salivarius UCC118TM as a probiotic-based therapeutic strategy to promote health through the upregulation of anti-inflammatory IL-10 and protect against dysbiosis during IBD.

Keywords: colitis; inflammation; microbiota; probiotic.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus SalivariusAccelerated Colitis RecoveryBeneficial
Large
Lactobacillus SalivariusEnhanced Inflammation ResolutionBeneficial
Moderate
Lactobacillus SalivariusEnhanced M2 Macrophage Marker ExpressionBeneficial
Moderate
Lactobacillus SalivariusIncreased Anti-Inflammatory Cytokine IL-10Beneficial
Moderate
Lactobacillus SalivariusRecovered Microbiome-associated DysbiosisBeneficial
Large
Lactobacillus SalivariusReduced Colitis SeverityBeneficial
Large
Lactobacillus salivarius UALs07 UASAccelerated Colitis RecoveryBeneficial
Large
Lactobacillus salivarius UALs07 UASEnhanced M2 Macrophage Marker ExpressionBeneficial
Moderate
Lactobacillus salivarius UCC118Improved Recovery From ColitisBeneficial
Large
Lactobacillus salivarius UCC118Increased Interleukin-10 LevelsBeneficial
Moderate
Lactobacillus salivarius UCC118Reduced Colitis SeverityBeneficial
Large
Lactobacillus salivarius UCC118Reduced DysbiosisBeneficial
Large
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.